|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:activities
|
progestin activity
|
|
gptkbp:affects
|
gptkb:ovulation
gptkb:menstrual_cycle
endometrial lining
cervical mucus
|
|
gptkbp:appointed_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:brand
|
Aygestin
Micronor
Nor-QD
|
|
gptkbp:clinical_trial
|
Phase III trials
Phase IV trials
|
|
gptkbp:contraindication
|
gptkb:healthcare_organization
liver disease
pregnancy
unexplained vaginal bleeding
|
|
gptkbp:developed_by
|
gptkb:Organon
|
|
gptkbp:discovered_by
|
1950s
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
combination with estrogen
single-agent
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
norethindrone
|
|
gptkbp:ingredients
|
C20 H26 N2 O2
|
|
gptkbp:interacts_with
|
gptkb:St._John's_Wort
antibiotics
anticonvulsants
HIV medications
|
|
gptkbp:is_available_on
|
generic drug
|
|
gptkbp:is_used_for
|
hormone replacement therapy
contraception
menstrual disorders
|
|
gptkbp:lifespan
|
8-12 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:United_Kingdom
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:research_focus
|
gptkb:endometriosis
hormonal balance
menstrual regulation
PCOS
|
|
gptkbp:side_effect
|
headache
nausea
weight gain
breast tenderness
mood changes
|
|
gptkbp:type_of
|
41542-31-2
|
|
gptkbp:bfsParent
|
gptkb:Necon_10/11
|
|
gptkbp:bfsLayer
|
6
|